Business Context and Reporting Period
This Form 10-Q covers the quarterly and nine-month periods ended September 30, 1994, for Eli Lilly & Co. The company operates primarily in pharmaceuticals, medical devices, diagnostics, and animal health. As of October 31, 1994, there were 292,204,808 shares of common stock outstanding.
Key Financial Metrics
| Metric | Q3 1994 | Q3 1993 | 9M 1994 | 9M 1993 |
|---|---|---|---|---|
| Net Sales | $1,817.4M | $1,530.6M | $5,132.9M | $4,651.6M |
| Net Income | $318.7M | $294.4M | $996.0M | $1,003.8M |
| Earnings Per Share | $1.10 | $1.00 | $3.44 | $3.42 |
| Operating Cash Flow (9M) | $989.6M (1994) vs $988.6M (1993) | |||
| Cash & Equivalents | $999.6M (Sep 30, 1994) vs $539.6M (Dec 31, 1993) | |||
| Total Debt | $1,912.9M (Sep 30, 1994) vs $1,360.0M (Dec 31, 1993) | |||
| Manufacturing Cost % of Sales | 31.8% | 30.5% | 31.6% | 29.7% |
Material Changes vs. Prior Period
- Sales Growth: Q3 sales increased 19% year-over-year, driven by a 25% increase in pharmaceutical sales. Prozac sales were particularly strong due to wholesaler inventory accumulation ahead of a price increase. International sales grew 22% in Q3.
- Profitability: Net income rose 8% in Q3 but declined slightly on a nine-month basis ($996.0M vs $1,003.8M) due to special charges and a higher effective tax rate (31.5% in 1994 vs 29.5% in 1993).
- Special Charges: The nine-month period included a $66.0 million pre-tax charge related to the voluntary recall of three liquid oral antibiotics and a $58.4 million charge for acquired in-process research from the Sphinx Pharmaceuticals acquisition.
- Debt Levels: Total debt increased by approximately $553 million, primarily due to bank borrowings by subsidiaries to fund dividends and preparations for the pending PCS Health Systems acquisition.
Guidance, Outlook, and Risks
- Acquisition: The company announced a definitive agreement to acquire PCS Health Systems, Inc. for $4 billion in cash, expected to close in November 1994. Financing will initially involve $4 billion in short-term and intermediate-term debt.
- Credit Ratings: Standard & Poor's and Moody's downgraded the company's long-term debt ratings (from AAA to AA and Aa1 to Aa3, respectively) due to the planned debt issuance for the PCS acquisition and anticipated competition for the antibiotic Ceclor.
- Product Risks: The company expects generic competition for Ceclor to have a material adverse effect on 1995 results. Management projects 1995 earnings from core pharmaceutical operations to be approximately $4.00 per share, excluding the PCS acquisition impact.
- Legal Contingencies: Significant litigation exists regarding product liability (Prozac, diethylstilbestrol), patent disputes, and environmental cleanup (Superfund). The company has accrued approximately $455 million for these liabilities, with estimated insurance recoverables of $160 million.
Investor Verification Checklist
- Verify the closing status and financing terms of the $4 billion PCS Health Systems acquisition.
- Monitor the impact of generic cefaclor entry on Ceclor sales volumes and margins in 1995.
- Review the trajectory of the $66 million antibiotic recall charge and any subsequent inventory write-offs.
- Assess the company's ability to service increased debt levels following the credit rating downgrades.
- Track developments in major product liability lawsuits (Prozac, DES) and potential changes in accrued liabilities.